Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944369 · ClinicalTrials.gov registry record · NA
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
A NA study, sponsored by Kaleido Biosciences.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03944369: Clinical Trial NA study, sponsored by Kaleido Biosciences.
NCT03944369 is a NA study that was terminated before completion, run by Kaleido Biosciences. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03944369, a NA study, was terminated before completion, sponsored by Kaleido Biosciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms.
Interventions
- OTHER No intervention
- OTHER KB109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2020-06-16 |
| Phase | NA |
Why NCT03944369 stopped before completion
NCT03944369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT03944369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03944369 about?
NCT03944369 is a clinical study titled "VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms". This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms.
What is the current status of trial NCT03944369?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2019-06-27. Estimated completion is 2020-06-16.
What interventions are being tested in trial NCT03944369?
The interventions under investigation include: No intervention (OTHER), KB109 (OTHER).
Who is sponsoring clinical trial NCT03944369?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03944369's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI